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proliferation to balloon injury in the rat by blocking the genetic 
message for the production of the growth factor IGF-1. 
The second agent to be tested is a chimeric hammerhead 
ribozyme homologous to an antisense region of the cell cycle 
regulating message cdc-2 ldnase, or proliferating cell nuclear 
antigen (PCNA), or both. We are the first group to show efficacy for 
ribozyme treatment in vivo, We demonstrated that local arterial 
delivery of these ribozymes inthe balloon-injured rat carotid artery 
blocks intimal hyperplasia by more than 60% and that it specifically 
hmcks out the target messages and the proteins. Ribozyme 
treatment has a theoretic advantage over antisense in that it is 
catalytic, thus regenerating itself, and the RNA/DNA chimer is 
resistant to cleavage by lyric enzymes. The third class of agents to be 
tested will be gene therapy using a polylyzine adenovirus vector 
carrying the gene for the tibozyme selected above. 
Before animal model testing, the kinetic of incorporation and 
release of each candidate agent will be characterized in vitro and 
compared with existing kinetic models of slab membrane behavior. 
Next, the tissue kinetics, bioactivity, and toxicity of the stent- 
delivered substance will be explored in the rabbit carotid artery, 
and, in the most promising cases, in the pig coronary arteries. 
Neal L. Eigler, MD 
Cedars Sinai Medical Center 
Los Angeles, Calif. 
MODIF ICAT ION OF  ART IF IC IAL  HEARTS BY 
GENE TRANSFER 
An estimated 4 million people in the United States have congestive 
heart disease. The annual death rate from this condition isapproxi- 
mately 500,000, and the reduction of these numbers i dependent 
on transplant surgery or a mechanical alternative, such as an 
artificial heart. The low number of donor hearts (about 2000 per 
year), coupled with the randomness of their availability, has lead to 
the use of ventricular assist devices as a short-term option to 
maintain patient well-being until a suitable donor heart becomes 
available. Pumps, such as the HeartMate left ventricular assist 
device (LVAD ) have been used with considerable success for as long 
as 18 months in the US. In the United Kingdom the use of the 
LYAD as a permanent alternative to transplantation has been 
adopted in certain health care institutions. Therefore, improve- 
ments in the performance ofthis type of device by enhancing the 
biocompatibility of the material-blood interface becomes an im- 
portant area for investigation. 
One avenue that has been studied for this purpose is the 
seeding of biomateriat surfaces with autologous cells. Intuitively, 
endothelial cells would appear to be the cell of choice for cardio- 
vascular prostheses. However, the seeding of the blood-contacting 
surfaces of a number of different prostheses with autologous 
endothelial cells to improve their biocompatibility has had limited 
success. Factors that contribute to failure include cellular senes- 
cence, poor attachment to biomaterial surfaces, and impaired 
production of the endothelial-derived factors desired for improve- 
ment in biocompatibility. In addition, anumber of prostheses, such 
as cardiac pumping devices, require a large number of cells for the 
initial seeding due to their large surface area. An alternate celi type 
that does not suffer from these disadvantages is smooth muscle. 
The latter can be isolated easily and expanded in cuimre without 
undergoing senescence; they also attach firmly to many biomate- 
rials. However, they exhibit properties that suggest that their use 
would be fraught with problems, because they not oniy have the 
capacity to proliferate uncontrollably but also present athrombo- 
genie surface. If these disadvantages could be overcome, autolo- 
gous smooth muscle cells would be ideal candidates for lining 
devices uch as the LVAD. 
Smooth muscle cell proliferation is controlled invivo by factors 
released by the endothelium, and one of these; endothelium- 
derived relaxing factor (EDRF), also contributes tothe inhibition 
of platelet adherence to the luminal endothelial cells. NO, the 
chemical identiw ofEDRF, synergizes with endothelinm-produced 
prostacyclin (PGI2) to prevent platelet activation. The recent 
advent of genetic engineering technology provides a way to modify 
the behavior of smooth muscle cells in a manner that allows them 
to mimic the endothelium. If smooth muscle ceils could be 
engineered with the capacity to produce NO and prostacyclin i  a 
constitutive manner, they could provide a nonproliferative, non- 
thrombogenic cell layer for coating biomaterial surfaces in contact 
with blood. Extensive studies have been carried with LVADs 
implanted in calves; therefore, the feasibility of using genetically 
engineered smooth muscle cells for the purposes described above 
was investigated using bovine cells. 
Initial studies used cells isolated from calf thoracic aorta; 
however, saphenous vein smooth muscle cells were also tested at 
each stage of the procedures described below to ensure that the 
findings with arterial-derived cells could be reproduced. Cells were 
grown in standard, minimum essential medium containing Earles 
salts and, in addition, 2 mmol/L glutamine, 20 mmol/L TES- 
NaOH, pH 7.3, 20 mmol/L HEPES-NaOH, pH 7.3, 100 
units/nil penicillin, and 100 units/ml streptomycin (MEMTH). 
Cells were transfected with plasmid constructs containing cDNA 
encoding either bovine endothelial NO synthase (NOS III), 
human prostaglandin H synthase (PGHS), rat GTP: cyclohydro- 
lase I (GTP:CH), or bovine endothelial cell growth factor 
(VEGF). Plasmid constructs were prepared by cloning into com- 
mercial Epstein-Barr virus-derived vectors (pREP 9 or pREP4) that 
retained the ability for episomal replication in mammalian host 
cells. Vectors contained sequences that rendered them resistant to 
either neomycin/G418 (pREP 9) or hygromycin (pREP4) , and the 
inserted coding sequences were driven off a Rous Sarcoma viral 
promoter. DNA was introduced into smooth muscle ceils either 
by square wave electroporation (400 volts, for 20/msec repeated 
20 times) or by use of commercial liposome preparations. After 
transfection, cells were placed in selection medium, which con- 
tained the components described for MEMTH plus the antibiotic 
specific for selection. Control ceils subjected to transfection pro- 
cedures in the absence of DNA died within 8 days when cultured 
in selection media. Antibiotic-resistant cells were grown to con- 
fluence and passaged by trypsinization and replating. This pro- 
cedure was repeated until expression levels of the inserted gene 
declined below levels of detection by Western analysis. In addi- 
tion, expression of NOS III was monitored by assay of nitrite 
anion levels in conditioned media, and this procedure was used 
as an indirect assay for the determination f GTP:CH expression. 
Production of 6-keto prostaglandin FI~ was used to assay PGHS 
activity in transfected cells. Bovine smooth muscle cells main- 
tained expression of NOS III for many passages in culture (12 
to 24), as determined by Western blot analysis using a monoclonal 
antibody specific to the endothelial ceil isoform of NOS. How- 
ever, the levels of NO produced were below the level of detection 
using the Greiss procedure for nitrite anion determination. I  the 
prcscnce of sepiapterin, a membrane-permeable, exogenous 
source of tetrahydrobiopterin (BH4), nitrite anion production by 
NOS III-transduced cells ranged from 12.54 + 1.19 to 
18.32 T- 2.11 nmol/106 cells. BH4 is an essential cofactor for the 
production of NO by NOS, and its synthesis i  regulated by the 
enzyme GTP :CH. This enzyme is constitutively active in a 
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number of cell types, including endothelial cells; however, smooth 
muscle cells do not express GTP:CH unless it is induced. This 
occurs in response to agonists, uch as prostacyclin, that elevate the 
levels of intracellular cyclic AME Therefore, treatment of pREP 9 
NOS 1II transfectants with a stable analog of PGI2, carbaprostacy- 
din, lead to production of NO (N02-), but this was not apparent in
cells transfected with the parent pREP 9 vector alone. 
The growth rates ofNOS III-transduced smooth muscle cells 
were significantly reduced as compared with control cells (pREP 9 
plasmid alone) in the presence of sepiapterin. This inhibition of 
growth was reversed significantly by inclusion of 400 gmol/L 
nitro-L-arginine in the culture medium. The presence of carba- 
prostacyclin elicited similar effects to those observed with sepiap- 
terin, and the growth inhibition of NOS llI-transduced cells was 
reversed by nitro-L-arginine. If smooth muscle cells were trans- 
fected with plasmid constructs encoding GTP:CH activity and 
then exposed to agonists (activators of protein kinase C, such as 
phorbol esters) that induce NOS (iNOS/NOS 1I) expression, they 
produced significant amounts of NO (N02-). This was not ob- 
served in cells transfected with control pREP 9 plasmid and exposed 
to the same NOS II-inducing agents. Expression of NOS II was 
confirmed ineach case byWestern blotting with a specific antibody. 
These findings are indicative of a possible added advantage to
the transduction fPGHS expression i smooth muscle ceils. The 
exposure of smooth muscle cells, transfected with NOS 1II, to PGI 2 
should result in the elevation of their intracellular levels of cyclic 
AMP sufficiently to induce GTP:CH activity and production of 
BH4. These events hould optimize production of NO by the 
transduced gene and thus obviate the necessity for the additional 
introduction of the GTP : CH gene into the smooth muscle cells to 
provide cofactor for NOS. 
The data demonstrate that proliferative hyperactivity, the first 
apparent drawback to the use of smooth muscle cells, in contrast to 
endothelial cells, as linings to cardiovascular p ostheses can be con- 
trolled by transduction fNOS expression. Growth rates were re- 
tarded by such genetic manipulation, but judicial use ofinhibitors 
ofNOS (nitro-L-arginine) allowed for high growth rates of trans- 
duced cells desirable during expansion of cell populations inculture 
to obtain sufficient cells for device-seeding purposes. The addi- 
tional beneficial effects of NO production, amely, passivation of 
platelets, remains to be demonstrated in experimental flow systems. 
The expression ofNOS III, which was maintained for several 
population doublings in the presence of G418, decreased rapidly 
with passage of cells in the absence of the selective pressure of 
antibiotic presence. It is intended that the transduced smooth 
muscle ceils will be seeded onto the internal surfaces of the LVAD 
before implantation athigh enough densities to form a confluent 
monolayer. Therefore, the number of population doublings that 
may occur after implantation i  the absence of the G418 selection 
pressure (resulting in the loss of NOS III expression) may be 
limited. Production of NO by the seeded cells will also limit the 
population doublings. Nonetheless, an additional strategy will be 
investigated in an attempt to maximize the advantages of having a 
cellular layer on the internal surfaces of LVADs. Smooth muscle 
cells will be transfected with VEGF (pREP 9 VEGF). Expression of 
VEGF will promote the growth of self-seeded, host endothelial 
cells over the smooth muscle cell layer. In LVAD pumps retrieved 
from patients, host-derived endothelial cells populate only those 
areas already covered with a pseudointima ofsmooth muscle-like 
cells. Therefore, host-derived endothelial cells may be capable of 
forming an endothelium-like covering. The source of these ndo- 
thelial cells remains controversial, however. 
In summary, smooth muscle cells will be engineered to behave 
as a pseudoendothelium during the initial phase of pump implan- 
tation. The production of NO, prostacyclin, and, if necessary, BH4 
will allow them to perform this function. At the same time, their 
production of a specific growth factor for endothelial cells (VEGF) 
will optimize their overgrowth by host endothelial cells. This will 
eventually ead to a cellular multllayer within the pump that mimics, 
to some extent, the structural organization ofa blood vessel wall. 
"The presencc of the host's own endothelial cells will hopefully 
maximize biocomparibllity and at the same time control platelet 
and smooth muscle activity. The engineered smooth muscle cells 
will provide atemporary pseudoendothelium and a substrata for the 
host to establish their own endothelial celi lining of the device. 
Timothy Scott-Burden, PhD 
Texas Heart Institute 
Houston, Tex. 
GENETIC  MODIF ICAT ION OF 
INTRAVASCULAR STENTS 
The use of intravascular stents as an adjunct for percutaneous 
transluminal revascularization is limited principally by two factors: 
acute thrombosis in the period immediately after deployment and 
neointimal proliferation resulting in delayed stenosis. We have 
investigated the potential of microporous bioresorbable polymer 
stents formed from blends of poly(Lqactic acid) (PLLA) and 
poly(caprolactone) (PCL) to function both to provide mechanical 
support o the vessel wall (to overcome lastic recoil) and as 
reservoirs for the delivery of therapeutic molecules (to enhance 
healing). Tubular stents have been fabricated by a flotation/pre- 
cipitation technique from 75:25, 50 : 50 and 25 : 75 PLLA:PCL 
blends, respectively. Porosity and degradation rate increased, and 
mechanical strength decreased with increasing PCL content. He- 
lical stents have been produced from 100% ELLA, 75:25 and 
50 : 50 PLLA:PCL by a number of means, including, casting- and 
extrusion/winding. Complex structures inwhich a tubular sheath 
is deposited on a helical skeleton have also been generated. Using 
a two-stage solvent swelling, surface interpenetration technique 
polyethylene oxide (PEO) has been incorporated into these stents 
to improve hydrophilicity. This technique has improved water and 
viral stock absorption sevenfold, potenti~ly permitting these modi- 
fied stents to function as carriers for drug delivery. Stents fabricated 
from the 75 : 25 PLLA: PCL blends, when modified in this manner, 
retain tensile, and compressive strength, with spring coefficients 
sufficient o stabilize vessels against elastic recoil, vasoconstrictive 
and hemodynamic drag forces. Because of the potential for direct 
gene transfer into a vessel wall to ameliorate thrombosis and 
neointimal proliferation, we have investigated the capacity of these 
polymer stents to function in the delivery of recombinant adenovi- 
rus vectors. Virus stock absorbs into and elutes from these devices 
in an infectious form in vitro, with kinetics suitable for gene 
delivery. In particular, the dwell times for gene transfer are 
increased over those available by some balloon deposition tech- 
niques. Successful gene transfer and expression has been demon- 
strated after implantation of 75:25 PLLA:PCL, 4.0 mm OD 
polymer stents impregnated with a recombinant adenovirus carry- 
ing a nuclear localizing betagalactosidase reporter gene into rabbit 
carotid arteries. Infection of cells spanning the arterial wall was 
demonstrated. These studies uggest that surface-modified, biore- 
sorbable polymer stents may ultimately be useful adjunctive devices 
for percutaneous transluminal revascularization. 
Robert Eberhart, PhD 
University of Texas Southwestern Medical Center 
Dallas, Tex. 
